Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562129 · ClinicalTrials.gov registry record · Phase 2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT04562129 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 29 participants, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04562129, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Interleukin-2
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562129
The ClinicalTrials.gov registry entry for NCT04562129 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (71% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04562129 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04562129 about?
NCT04562129 is a clinical study titled "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients". The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
What is the current status of trial NCT04562129?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-09-24. Estimated completion is 2029-11.
What conditions does trial NCT04562129 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III, Inoperable Disease.
What interventions are being tested in trial NCT04562129?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT04562129?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04562129 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.